Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation

Jae Suk Ahn1, Mala L Radhakrishnan, Marina Mapelli

  • 1Department of Neurology and Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Chemistry & Biology
|July 26, 2005
PubMed

Insights

Researchers identified three novel inhibitors targeting Cyclin-dependent kinase 5 (Cdk5), a key factor in neurological disorders. These compounds offer distinct mechanisms for developing new Cdk5-based therapies.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Drug Discovery

Background:

  • Cyclin-dependent kinase 5 (Cdk5) is implicated in neurological disorders.
  • Abnormal tau phosphorylation by Cdk5 contributes to neurofibrillary tangles.

Purpose of the Study:

  • To identify and characterize inhibitors of Cdk5-mediated tau phosphorylation.
  • To explore structure-activity relationships for Cdk5 inhibitor design.

Main Methods:

  • High-throughput screening for Cdk5 inhibitors.
  • Cocrystallography to determine inhibitor-bound Cdk5 structures.
  • Structure-activity relationship (SAR) analysis.

Main Results:

  • Identified three compounds with distinct inhibitory mechanisms against Cdk5.
  • Characterized ATP-competitive and tau-competitive inhibitors.
  • Mapped the Cdk5 ATP binding pocket and identified an unfilled region.

Conclusions:

  • Cdk5 structure guides the design of potent and selective inhibitors.
  • Identified lead compounds for structure-based drug design targeting Cdk5.
  • Potential therapeutic strategies for neurological diseases involving Cdk5.

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...